Tafasitamab (Monjuvi)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity

Diseases for which it is used

History of changes in FDA indication

History of changes in EMA indication

  • 2021-08-26: Initial conditional approval as Minjuvi

History of changes in Health Canada indication

Also known as

  • Code names: MOR-208, MOR-00208, XmAb-5574
  • Generic name: tafasitamab-cxix
  • Brand name: Minjuvi, Monjuvi